Globus Medical Inc. Class A Common Stock vs Liberty Global Ltd Class C — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Liberty Global Ltd Class C trades at $8.03 (market cap $2.94B). The key difference: Globus Medical Inc. Class A Common Stock is far larger — about 3.5× Liberty Global Ltd Class C's market cap, and Globus Medical Inc. Class A Common Stock is trading nearer its 52-week high, Liberty Global Ltd Class C nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Liberty Global Ltd Class C for 20 Days on average.
| GMED | LBTYK | |
|---|---|---|
Market Cap | $10.25B | $2.94B |
Volume | 1,108,124 | 1,441,876 |
Sector | Health | Media |
52-Week High | $96.82 | $12.67 |
52-Week Low | $58.33 | $8.03 |
Typical Hold Time | 0 Days | 20 Days |
Enterprise Value | $9.76B | $9.60B |
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Liberty Global (LBTYK) trades at $8.41, showing minimal daily movement with a 0.24% gain. The stock faces bearish technical signals but maintains strong analyst support with 69% buy ratings and a $12.67 consensus target. Recent financials show mixed performance with negative net income margins (-62.14%) despite solid gross margins (67.17%), while strategic moves like the Ziggo Group spin-off and AI partnerships aim to unlock value by 2027.
The outlook remains cautiously optimistic given the significant upside to analyst targets and ongoing corporate restructuring. Key risks include persistent profitability challenges and execution risks around the Ziggo listing. The stock's deep value proposition (P/S 0.59, P/B 0.31) offers potential for patient investors despite near-term volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →Liberty Global is a world leader in converged broadband, video, and mobile communications. It operates large-scale fiber and 5G networks across Europe, providing essential digital services to millions of customers.
Read more on LBTYK →